05:18 AM EDT, 06/03/2024 (MT Newswires) -- GSK (GSK) said on Sunday that an interim analysis of the phase III trial evaluating its experimental therapy belantamab mafodotin, in combination with pomalidomide plus dexamethasone, showed promise as a second-line and later treatment for a type of blood cancer.

The study showed statistically significant and clinically meaningful improvement in progression-free survival for patients on belantamab mafodotin combination therapy compared to standard of care, bortezomib plus PomDex, the company said.

It added that overall survival trends improved but were not statistically significant at the interim stage.

The combination therapy also consistently demonstrated clinically meaningful improvements across secondary efficacy endpoints.

Price: 44.83, Change: +0.06, Percent Change: +0.13